

A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomised study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design.

Submission date 12/10/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 12/10/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/07/2018	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Cornel Pater

Contact details
Hans-Boeckler Allee 20
Hannover
Germany
30173
+49 (0)511 857 2074
cornel.pater@solway.com

Additional identifiers

Protocol serial number

S171.3.012

Study information

Scientific Title

A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomised study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design.

Acronym

ASTRID (Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril and type 2 Diabetics)

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Essential Hypertension grade I and II

Interventions

Single, double- and triple- combination antihypertensive therapy, active controlled (monotherapy [eprosartan versus ramipril] followed by addition of hydrochlorothiazide as second agent and moxonidine as a third agent).

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/01/2006

Eligibility

Key inclusion criteria

Investigative centers from eight European countries and Canada (primary and secondary care) targeting patients with grade I - II hypertension and associated diabetes mellitus type 2. Goal blood pressure (BP) targeted: below 130/80 mmHg.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2004

Date of final enrolment

01/01/2006

Locations

Countries of recruitment

United Kingdom

Germany

Study participating centre

Hans-Boeckler Allee 20

Hannover

Germany

30173

Sponsor information

Organisation

Solvay Pharmaceuticals (Germany)

ROR

<https://ror.org/01xsrc43>

Funder(s)

Funder type

Industry

Funder Name

GPS Solvay Pharmaceuticals

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	Protocol	01/10/2004		Yes	No